CT Colonography and Telerad Meet Rural Screening Needs

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 11
Volume 19
Issue 11

CT colonography is feasible in remote health centers where optimal colonoscopy is limited, according to a study from the University of Arizona in Tucson.

CT colonography is feasible in remote health centers where optimal colonoscopy is limited, according to a study from the University of Arizona in Tucson.

The study was performed at Fort Defiance Indian Hospital in Fort Defiance and at Tuba City Regional Health Care Center in Tuba City. CT technologists were given on-site instruction on CTC and began performing screening exams. A total of 321 studies were transferred to the Tucson hospital for assessment, with reports returned via a teleradiology information system. “Overall image quality assessment of stool, fluid, and distention revealed that about 92% of patients had diagnostic quality examinations with respect to each image quality parameter,” said lead author Arnold C. Friedman, MD (AJR 195:1110-1117, 2010). He stressed that in order for this set up to work, CT technologists need to be properly trained and methods of image transmission need to be clearly defined.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content